USA flag logo/image

An Official Website of the United States Government

Liposomal TNF¿Potential Application as Cancer Therapy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
22014
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
22014
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Vestar, Inc.
650 Cliffside Drive San Dimas, CA 91773
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1995
Title: Liposomal TNF¿Potential Application as Cancer Therapy
Agency: HHS
Contract: N/A
Award Amount: $596,469.00
 

Abstract:

Preliminary findings indicate that liposomal tumor necrosis factor (TNF) has potential application as an anti-tumor therapy. In initial studies, it retains cytotoxic activity against cancer cells in culture and yet elicits none of the toxic effects associated with TNF in healthy mice. These studies will be continued and expanded. The goal is to establish the in vivo efficacy of the formulation as a cancer treatment. To this end, liposomal TNF will be produced in sufficient quantity to define (1) its cytotoxic activity against murine B16 melanoma cells, (2) its lethal dose in B57CI/6 mice that bear B16 melanoma implants, and (3) its in vivo effectiveness as a treatment for murine melanoma. Formulations containing murine and human TNF-alpha will be compared because cross-species variation in TNF-receptor interactions are known. Identically prepared liposomes without TNF-alpha will serve as a control. In light of the tremendous effort that has gone into trying to extend TNF's very narrow therapeutic index, production of an active, clinically acceptable form of TNF would prove to be a major milestone.

Principal Investigator:

Gary Fujii
7143944000

Business Contact:

Small Business Information at Submission:

Vestar, Inc.
650 Cliffside Drive San Dimas, CA 91773

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No